Beyond anaemia management: Evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models

Oncology

Volumn 69, Issue SUPPL. 2, 2005, Pages 22-30

  Boogaerts, Marc ^a   Mittelman, Moshe ^b   Vaupel, Peter ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b TEL AVIV UNIVERSITY   (Israel)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cancer; Central nervous system; Erythropoietin; Hypoxia; Multiple myeloma; Stroke

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ALLERGIC ENCEPHALOMYELITIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BLUNT TRAUMA; BRAIN INFARCTION SIZE; BREAST CANCER; CANCER; CANCER INHIBITION; CANCER THERAPY; DISEASE COURSE; HEMOGLOBIN DETERMINATION; HUMAN; HYPOXIA; IMMUNE SYSTEM; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STROKE; T LYMPHOCYTE; TUMOR CELL;

ANEMIA, HYPOCHROMIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL HYPOXIA; CENTRAL NERVOUS SYSTEM DISEASES; CHEMOTHERAPY, ADJUVANT; COGNITION; ERYTHROPOIETIN, RECOMBINANT; HUMANS; MULTIPLE MYELOMA; NEOPLASMS; PILOT PROJECTS;

EID: 27144472921     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088285     Document Type: Article

References (63)

1. Means RT Jr: Advances in the anemia of chronic disease. Int J Hematol 1999;70:7-12.
2. Cella D: Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25:43-46.
3. Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001;91:2214-2221.
4. Van Belle SJ, Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11.
5. Glaspy J, Beguin Y: Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon®). Oncology 2005;69(suppl 2):8-16.
6. Lappin TR, Maxwell AP, Johnston PG: EPO's alter ego: erythropoietin has multiple actions. Stem Cells 2002;20:485-492.
7. Fisher JW: Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003;228:1-14.
8. Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. JAMA 2005;293:90-95.
9. Jelkmann W: Molecular biology of erythropoietin. Intern Med 2004;43:649-659.
10. Buemi M, Cavallaro E, Floccari F, Sturiale A, Aloisi C, Trimarchi M, Corica F, Frisina N: The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003;62:228-236.
11. Marti HH, Bernaudin M, Petit E, Bauer C: Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol Sci 2000;15:225-229.
12. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R: Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997;76:105-116.
13. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R: In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95:4635-4640.
14. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E: A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999;19:643-651.
15. Juul SE, Anderson DK, Li Y, Christensen RD: Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998;43:40-49.
16. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R: Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 1998;253:26-32.
17. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri L, Cerami A: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-10531.
18. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, Reme CE: HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002;8:718-724.
19. Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E: Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev 2004;27:113-120.
20. Sekiguchi Y, Kikuchi S, Myers RR, Campana WM: ISSLS prize winner: Erythropoietin inhibits spinal neuronal apoptosis and pain following nerve root crush. Spine 2003;28:2577-2584.
21. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P: Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971-975.
22. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
23. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-650.
24. O'Shaughnessy JA: Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002;3:S116-S120.
25. Vaupel P, Thews O, Mayer A, Höckel S, Höckel M: Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol 2002;178:727-731.
26. Höckel M, Schienger K, Aral B, Mitze M, Schäffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
27. Vaupel P, Briest S, Höckel M: Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr 2002;152:334-342.
28. Vaupel P, Thews O, Höckel M: Treatment resistance of solid tumours: role of hypoxia and anaemia. Med Oncol 2001;18:243-259.
29. Vaupel P, Mayer A, Briest S, Höckel M: Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 2003;63:7634-7637.
30. Höckel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-276.
31. Vaupel P, Dunst J, Engert A, Fandrey J, Feyer P, Freund M, Jelkmann W: Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia. Onkologie 2005;28:216-221.
32. Höckel M, Schlenger K, Höckel S, Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59:4525-4528.
33. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
34. Glaser CM, Millesi W, Kornek GV, Lang S, Schüll B, Watzinger F, Selzer E, Lavey RS: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-715.
35. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J; Aranesp 980297 Study Group: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
36. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
37. Larsson AM, Landberg G, Pahlman S, Albertsson M: Erythropoietin enhances response to treatment in patients with advanced breast cancer. Acta Oncol 2004;43:594-597.
38. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
39. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-3565.
40. Batra S, Perelman N, Luck LR, Shimada H, Malik P: Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83:1477-1487.
41. Dagnon K, Pacary E, Commo F, Antoine M, Bernaudin M, Bernaudin JF, Callard P: Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 2005;11:993-999.
42. Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA: Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 2005;11:20-27.
43. Westphal G, Niederberger E, Blum C, Wollman Y, Knoch TA, Rebel W, Debus J, Friedrich E: Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002;88:150-159.
44. Berdel WE, Oberberg D, Reufi B, Thiel E: Studies on the role of recombinant human erythropoietin in the growth regulation of non-hematopoietic tumor cells in vitro. Ann Hematol 1991;63:5-8.
45. Rosti V, Pedrazzoli P, Ponchio L, Zibera C, Novella A, Lucotti C, Della Cuna GR, Cazzola M: Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 1993;78:208-212.
46. Selzer E, Wacheck V, Kodym R, Schlagbauer-Wadl H, Schlegel W, Pehamberger H, Jansen B: Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000;10:421-426.
47. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, Haroon ZA: Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911-918.
48. Westenfelder C, Baranowski RL: Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647-657.
49. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H: Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-1029.
50. Farrell F, Lee A: The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004;9:18-30.
51. Stüben G, Thews O, Pöttgen C, Knühmann K, Vaupel P, Stuschke M: Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-350.
52. Stüben G, Thews O, Pöttgen C, Knühmann K, Sack H, Stuschke M, Vaupel P: Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 2003;179:620-625.
53. Stüben G, Pöttgen C, Knühmann K, Schmidt K, Stuschke M, Thews O, Vaupel P: Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003;55:1358-1362.
54. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752-756.
55. Thews O, Kelleher DK, Vaupel P: Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-1361.
56. Aapro M, Dunst J, Morère JF, Nowrousian MR, Huber M, Burger HU: Effect of epoetin beta on tumour progression and survival in patients with cancer: a meta-analysis of controlled clinical studies. Ann Oncol 2004;15(suppl 3):A841.
57. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-498.
58. Mittelman M, Zeidman A, Kanter P, Katz O, Oster H, Rund D, Neumann D: Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies. Eur J Haematol 2004;72:155-165.
59. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B: Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-393.
60. Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A: Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol 1997;98:204-210.
61. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N: Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001;98:5181-5186.
62. Prutchi-Sagiv S, Katz O, Yeyni L, Skaat A, Barzilay E, Neumann D, Mittelman M: Recombinant human erythropoietin (rHuEpo) as an anti-myeloma immunomodulatory agent. Blood 2004;104:304b (abstract 4887).
63. Baz R, Brand C, McGowan B, Yiannaki E, Hussein MA: High dose recombinant erythropoietin use is associated with increased overall survival in patients with multiple myeloma. Proc ASCO 2005;23(suppl 16):abstract 6621.